TY - JOUR
T1 - Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer
T2 - Implications for Clinical Trials
AU - Rashdan, Sawsan
AU - Yang, Hui
AU - Le, Tri
AU - Selby, Christopher
AU - Gerber, David E.
AU - Alvarez, Carlos A.
N1 - Funding Information:
The present study was supported in part by a National Cancer Institute (NCI) Midcareer Investigator Award in Patient-Oriented Research (Grant K24 CA201543-01, to DEG), the NCI Small Grants Program for Cancer Research (Grant 1R03CA191875, to DEG), an NCI National Clinical Trials Network Lead Academic Performance Site Award (Grant 5U10CA180870, to DEG), National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award (Grant K08 DK101602, to CAA), the UT Southwestern Center for Translational Medicine (Grant UL1 TR001105, to CAA), and the Cancer Prevention and Research Institute of Texas (Grant CPRIT 50C1324901 to CAA). The authors thank Ms Dru Gray for providing assistance with manuscript preparation, and Helen Mayo, MLS, for providing assistance with literature searches.
Funding Information:
Sawsan Rashdan serves on the advisory board at AstraZeneca and has also received funding for a research study from AstraZeneca. David E. Gerber receives research funding from AstraZeneca, BerGenBio, and Karyopharm, owns stock in Gilead, and has received consulting fees from Samsung Bioepis. Carlos A. Alvarez receives research funding from Merck. Hui Yang, Tri Le, and Christopher Selby have no conflicts of interest to declare.
Funding Information:
Carlos A. Alvarez received support from the National Institutes of Health (K08DK101602), Agency for Healthcare Research and Quality (R24HS022418), and Cancer Prevention and Research Institute of Texas (17003). The funding sources had no role in the study’s design, conduct, and reporting.
Funding Information:
The present study was supported in part by a National Cancer Institute (NCI) Midcareer Investigator Award in Patient-Oriented Research (Grant K24 CA201543-01, to DEG), the NCI Small Grants Program for Cancer Research (Grant 1R03CA191875, to DEG), an NCI National Clinical Trials Network Lead Academic Performance Site Award (Grant 5U10CA180870, to DEG), National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award (Grant K08 DK101602, to CAA), the UT Southwestern Center for Translational Medicine (Grant UL1 TR001105, to CAA), and the Cancer Prevention and Research Institute of Texas (Grant CPRIT 50C1324901 to CAA). The authors thank Ms Dru Gray for providing assistance with manuscript preparation, and Helen Mayo, MLS, for providing assistance with literature searches.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.
PY - 2021/2
Y1 - 2021/2
N2 - Background: The overall prevalence of potential drug–drug interactions (DDIs) among patients with lung cancer is unknown. Objective: The objective of this study was to determine the prevalence of potential DDIs and major DDIs among individuals newly diagnosed with lung cancer in a national cohort. Patients and Methods: We performed a retrospective cross-sectional study of adult patients in the United States Veterans’ Affairs (VA) medical system diagnosed with lung cancer between 2003 and 2016. The primary endpoint was the prevalence of prescriptions for medications associated with any potential DDIs during the 3 months leading up to and including the date of lung cancer diagnosis. The secondary endpoint was the prevalence of prescriptions associated with major DDIs during the same time period. Results: Overall, 280,068 patients were included in the study; 55.9% of patients were prescribed medications associated with potential DDIs, while 5.3% received prescriptions for medications associated with major DDIs. Among the 20 most commonly prescribed drugs associated with potential DDIs, only two were associated with major DDIs. Conclusion: Medications with potential DDIs are prescribed to the majority of patients with lung cancer; however, only about 5% of patients are prescribed medications with major DDIs that might be prohibited in certain clinical trials.
AB - Background: The overall prevalence of potential drug–drug interactions (DDIs) among patients with lung cancer is unknown. Objective: The objective of this study was to determine the prevalence of potential DDIs and major DDIs among individuals newly diagnosed with lung cancer in a national cohort. Patients and Methods: We performed a retrospective cross-sectional study of adult patients in the United States Veterans’ Affairs (VA) medical system diagnosed with lung cancer between 2003 and 2016. The primary endpoint was the prevalence of prescriptions for medications associated with any potential DDIs during the 3 months leading up to and including the date of lung cancer diagnosis. The secondary endpoint was the prevalence of prescriptions associated with major DDIs during the same time period. Results: Overall, 280,068 patients were included in the study; 55.9% of patients were prescribed medications associated with potential DDIs, while 5.3% received prescriptions for medications associated with major DDIs. Among the 20 most commonly prescribed drugs associated with potential DDIs, only two were associated with major DDIs. Conclusion: Medications with potential DDIs are prescribed to the majority of patients with lung cancer; however, only about 5% of patients are prescribed medications with major DDIs that might be prohibited in certain clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85099080327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099080327&partnerID=8YFLogxK
U2 - 10.1007/s40261-020-00994-4
DO - 10.1007/s40261-020-00994-4
M3 - Article
C2 - 33417195
AN - SCOPUS:85099080327
SN - 1173-2563
VL - 41
SP - 161
EP - 167
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 2
ER -